ArticlePloS one2024
Co-infection mathematical model for HIV/AIDS and tuberculosis with optimal control in Ethiopia.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanistic Models of Virus-Bacteria Co-Infections in Humans: A Systematic Review of Methods and Assumptions.Pathogens (Basel, Switzerland) · 2025Pooled it
- The impact of treatment accessibility on HIV-TB co-infection: a comparative fractional-order modeling approach.BMC infectious diseases · 2026Article
- Mathematical model analysis of drug resistance TB dynamics with immigrants and impact of media efficiency.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-epidemics of HIV/AIDS and Tuberculosis (TB) outbreak is one of a serious disease in Ethiopia that demands integrative approaches to combat its transmission. In contrast, epidemiological co-infection models often considered a single latent case and recovered individuals with TB. To bridge this gap, we presented a new optimal HIV-TB co-infection model that considers both high risk and low risk latent TB cases with taking into account preventive efforts of both HIV and TB diseases, case finding for TB and HIV/AIDS treatment. This study aimed to develop optimal HIV/AIDS-TB co-infection mathematical model to explore the best cost-effective measure to mitigate the disease burden. The model is analysed analytically by firstly segregating TB and HIV only sub models followed by the full TB-HIV co-infection model. The Disease Free Equilibrium (DFE) and Endemic Equilibrium (EE) points are found and the basic reproduction number R0 is obtained using the next generation matrix method (NGM). Based on the threshold value R0, the stabilities of equilibria for each sub-model are analysed. The DFE point is locally asymptotically stable when R0 < 1 and unstable when R0 > 1. The EE point is also asymptotically stable when R0 > 1 and does not exist otherwise. At R0 = 1, the existence of backward bifurcation phenomena is discussed. To curtail the cost and disease fatality, an optimal control model is formulated via time based controlling efforts. The optimal mathematical model is analysed both analytically and numerically. The numerical results are presented for two or more control measures at a time. In addition, the Incremental Cost-Effectiveness Ratio(ICER) has identified the best strategy which is crucial in limited resource. Hence, the model outcomes illustrated that applying HIV/AIDS prevention efforts and TB case finding concurrently is the most cost-effective strategy to offer substantial relief from the burden of the pandemic in the community. All results found in this study have significant public health lessons. We anticipated that the results will notify evidence based approaches to control the disease. Thus, this study will aids in the fight against HIV/AIDS, TB, and their co-infection policy-makers and other concerned organizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.